TA-1
Thymosin Alpha-1 Fragment
Overview
TA-1 refers to short active fragments of Thymosin Alpha-1 that retain immunomodulatory activity with potentially improved pharmacokinetics. While full Thymosin Alpha-1 (documented separately as Thymosin Alpha-1 in this database) has extensive clinical evidence TA-1 fragments represent an area of active investigation for more targeted immune modulation. This entry covers research into the minimal active sequence required for Thymosin Alpha-1's immunological effects and the development of next-generation immune modulators derived from this peptide.
Where does TA-1 sit?
See how this peptide compares across all 70 peptides in our database.
Mechanism of Action
TA-1 fragments act on dendritic cells and T-lymphocytes through similar mechanisms to full Thymosin Alpha-1 — enhancing MHC class II expression improving antigen presentation and stimulating Th1 cytokine production particularly interferon-gamma and interleukin-2. The minimal active fragment retains the ability to enhance natural killer cell activity and restore T-cell function in immunocompromised states. Research into TA-1 fragments aims to identify the smallest sequence that retains full biological activity allowing for more economical synthesis and potentially improved tissue penetration compared to the full 28-amino-acid parent peptide.
Dosage Information
Typical Dose
1.6 mg (equivalent to Thymosin Alpha-1 dosing)
Frequency
Twice weekly
Administration
Subcutaneous injection
Notes
Limited differentiation from full Thymosin Alpha-1 in practice. See Thymosin Alpha-1 entry for the primary clinical evidence base.
Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1.6 mg (equivalent to Thymosin Alpha-1 dosing)
- Frequency
- Twice weekly
- References
- 0 curated + 50 from PubMed
- Evidence Score
- 26.2 / 100